Company Information

KILITCH DRUGS (INDIA) LTD.

NSE : KILITCHBSE : 524500ISIN CODE : INE729D01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE358.6010.1 (+2.9 %)
PREV CLOSE ( ) 348.50
OPEN PRICE ( ) 340.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3022
TODAY'S LOW / HIGH ( )340.80 367.70
52 WK LOW / HIGH ( )157 469.85
NSE359.2511.5 (+3.31 %)
PREV CLOSE( ) 347.75
OPEN PRICE ( ) 352.30
BID PRICE (QTY) 359.25 (100)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13522
TODAY'S LOW / HIGH( ) 340.50 365.10
52 WK LOW / HIGH ( )165.4 470
Managing DirectorMukund P Mehta
Company SecretaryPushpa Nyoupane
Non Executive Independent DirectorHemang Engineer
Vasudev Krishna Murti
Venkita Subramanian Rajan
Whole Time DirectorBhavin Mehta
Mira Mehta
Incorporation Year : 1992

Registered Office :

Address : C 301/2 M I D C,T T C Industrial Area,Pawane Village Navi Mumbai,
Maharashtra-400705 .

Phone : 022-62996300

Email :  info@kilitch.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.